Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595823 | 0.73 | MARS2 (0.84) | MARS2POLBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL23419563 | 0.73 | MARS2 (0.46) | MARS2POLBMAPTSMN1; SMN2 | |
| SCHEMBL20596598 | 0.68 | F10 (0.43) | MARS2POLBMAPTSMN1; SMN2 | |
| SCHEMBL23419425 | 0.66 | MARS2 (0.37) | MARS2POLBMAPTRAB9A | |
| SCHEMBL20596250 | 0.65 | MARS2 (0.79) | MARS2 | |
| SCHEMBL20595875 | 0.64 | MARS2 (1.00) | MARS2POLBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20596247 | 0.63 | MARS2 (1.00) | MARS2POLBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20596671 | 0.63 | MARS2 (0.54) | MARS2RAB9A | |
| SCHEMBL20596512 | 0.63 | F10 (0.44) | MARS2POLBMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20595860 | 0.62 | MARS2 (0.84) | MARS2POLBMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885POLB 424/4885MAPT 3686/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MARS2 5/4885POLB 459/4885MAPT 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.